Delcath Systems ( NASDAQ: DCTH ) stock jumped 15% Tuesday after the company reported positive results from a retrospective study of its Hepzato Kit in the treatment of patients with liver metastases from uveal melanoma. The study, which was published in the Annals of Surgical Oncology , showed an overall median progression-free survival of 15.4 months for patients who had received Hepzato Kit as a first-line therapy, compared with 8.
8 months for those who had received immunotherapy and 9.2 months for other liver-directed therapies. As a second-line treatment, those treated with Hepzato Kit had a median progression-free survival of 22.
2 months, versus 14.7 months for those who received immunotherapy and 7.5 months for other liver-directed therapies.
The study also showed significantly longer hepatic progression-free survival for those who received Hepzato Kit versus immunotherapy or other liver-directed therapies, according to a statement ..
